The protocol : Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel. / Zelenskaya, E. M.; Barbarash, O. L.; Ganyukov, V. I. et al.
In: Russian Journal of Cardiology, Vol. 150, No. 10, 2017, p. 113-117.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The protocol
T2 - Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel
AU - Zelenskaya, E. M.
AU - Barbarash, O. L.
AU - Ganyukov, V. I.
AU - Kochergin, N. A.
AU - Apartsin, K. A.
AU - Gorokhova, A. V.
AU - Papeshina, S. A.
AU - Nikolaev, K. Yu
AU - Batueva, K. Yu
AU - Yankovskaya, S. V.
AU - Tronin, O. V.
AU - Lifshits, G. I.
PY - 2017
Y1 - 2017
N2 - Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.
AB - Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.
KW - Clopidogrel
KW - CYP2C19
KW - Stent thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85035046182&partnerID=8YFLogxK
U2 - 10.15829/1560-4071-2017-10-113-117
DO - 10.15829/1560-4071-2017-10-113-117
M3 - Article
AN - SCOPUS:85035046182
VL - 150
SP - 113
EP - 117
JO - Российский кардиологический журнал
JF - Российский кардиологический журнал
SN - 1560-4071
IS - 10
ER -
ID: 9673322